Compare Arqit Quantum Inc (ARQQ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arqit Quantum Inc vs TransMedics Group Inc — how do they compare? Arqit Quantum Inc trades at $23.52 (market cap $424.79M), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 7.3× Arqit Quantum Inc's market cap. Which is the better fit depends on your goals.
| ARQQ | TMDX | |
|---|---|---|
Market Cap | $424.79M | $3.10B |
Sector | Technology | Technology |
52-Week High | $58.27 | $150.42 |
52-Week Low | $11.78 | $61.99 |
Enterprise Value | $398.10M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $23.72, up 4.91% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows explosive revenue growth but deep losses, with a P/S ratio of 352.9 reflecting high growth expectations. Recent news highlights a proof-of-concept with nLighten and strong H1 2026 revenue growth of 829% year-over-year, signaling commercial traction in quantum-safe encryption.
Outlook hinges on scaling revenue to offset high costs, with analyst sentiment split evenly between Buy and Hold. Key risks include sustained cash burn and competitive pressure, but government and telecom deals offer upside if execution improves.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
